Aliases & Classifications for Motion Sickness

MalaCards integrated aliases for Motion Sickness:

Name: Motion Sickness 57 12 43 42 44 15 17 71 32
Airsickness 43 71
Carsickness 43 71
Seasickness 43 71
Travel Sickness 12
Riders' Vertigo 43

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
not likely mendelian, but shows familial aggregation


Classifications:



External Ids:

Disease Ontology 12 DOID:2951
OMIM® 57 158280
ICD9CM 34 994.6
MeSH 44 D009041
NCIt 50 C34824
SNOMED-CT 67 37031009
ICD10 32 T75.3
MedGen 41 C0026603
SNOMED-CT via HPO 68 88425004
UMLS 71 C0001882 C0007297 C0026603 more

Summaries for Motion Sickness

MedlinePlus : 42 Motion sickness is a common problem in people traveling by car, train, airplanes, and especially boats. Anyone can get it, but it is more common in children, pregnant women, and people taking certain medicines. Motion sickness can start suddenly, with a queasy feeling and cold sweats. It can then lead to dizziness and nausea and vomiting. Your brain senses movement by getting signals from your inner ears, eyes, muscles, and joints. When it gets signals that do not match, you can get motion sickness. For example, if you are reading on your phone while riding a bus, your eyes are focused on something that is not moving, but your inner ear senses motion. Where you sit can make a difference. The front seat of a car, forward cars of a train, upper deck on a boat or wing seats in a plane may give you a smoother ride. Looking out into the distance - instead of trying to read or look at something in the vehicle - can also help. Centers for Disease Control and Prevention

MalaCards based summary : Motion Sickness, also known as airsickness, is related to space motion sickness and cyclic vomiting syndrome, and has symptoms including nausea and vomiting, constipation and polydipsia. An important gene associated with Motion Sickness is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Diphenhydramine and Promethazine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and heart, and related phenotypes are abnormality of the nervous system and adipose tissue

MedlinePlus Genetics : 43 Motion sickness is a common condition characterized by a feeling of unwellness brought on by certain kinds of movement. The usual symptoms include dizziness, pale skin (pallor), and sweating, followed by nausea and vomiting. Affected individuals may also experience rapid breathing (hyperventilation), headache, restlessness, and drowsiness. These symptoms can be triggered by many kinds of motion, particularly traveling in a car, bus, train, airplane, or boat. Amusement park rides, skiing, and virtual reality environments can also induce motion sickness.

Wikipedia : 74 Motion sickness occurs due to a difference between actual and expected motion. Symptoms commonly include... more...

More information from OMIM: 158280

Related Diseases for Motion Sickness

Diseases related to Motion Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
# Related Disease Score Top Affiliating Genes
1 space motion sickness 32.7 HRH1 FOS EFHD2
2 cyclic vomiting syndrome 30.2 OPRM1 HTR3A
3 sleep disorder 29.6 TAC1 POMC HTR1A HRH1 FOS
4 migraine with or without aura 1 29.6 TACR1 TAC1 POMC OPRM1 HTR3A HTR1B
5 anxiety 29.3 TAC1 POMC OPRM1 HTR3A HTR1B HTR1A
6 major depressive disorder 28.7 TACR1 TAC1 POMC OPRM1 HTR3A HTR1B
7 pathologic nystagmus 10.7
8 pica disease 10.5
9 seizures, scoliosis, and macrocephaly/microcephaly syndrome 10.4
10 neurotrophic keratopathy 10.3 TACR1 TAC1
11 detrusor sphincter dyssynergia 10.3 TAC1 HTR1A
12 causalgia 10.3 TACR1 TAC1
13 telogen effluvium 10.3 TACR1 TAC1
14 epicondylitis 10.3 TACR1 TAC1
15 retinitis pigmentosa 67 10.3 TACR1 TAC1
16 headache 10.3
17 femoral cancer 10.3 TAC1 FOS
18 anterograde amnesia 10.3 HTR1A FOS
19 serotonin syndrome 10.3 TAC1 HTR3A HTR1A
20 social phobia 10.3 TACR1 HTR3A HTR1A
21 glossopharyngeal neuralgia 10.2 TAC1 POMC
22 myofascial pain syndrome 10.2 TAC1 POMC
23 neurodermatitis 10.2 TAC1 POMC
24 arachnoiditis 10.2 TAC1 POMC
25 ataxia and polyneuropathy, adult-onset 10.2
26 atypical depressive disorder 10.2 POMC HTR1A
27 hypochondriasis 10.2 POMC HTR1A
28 adjustment disorder 10.2 POMC HTR1A
29 diamond-blackfan anemia 5 10.2 HTR1A FOS
30 inappropriate adh syndrome 10.2 POMC AQP1
31 allergic disease 10.2
32 tremor 10.2
33 acute stress disorder 10.2 POMC HTR1A
34 separation anxiety disorder 10.2 OPRM1 HTR1A
35 neurotic disorder 10.2 POMC PCSK5 HTR1A
36 barbiturate abuse 10.2 POMC OPRM1
37 hematuria, benign familial 10.2 HTR1A HRH1 FOS
38 retrograde amnesia 10.1 POMC HTR1A FOS
39 complex regional pain syndrome 10.1 TACR1 TAC1 POMC
40 syncope 10.1
41 chronic rhinitis 10.1 TAC1 HRH1
42 intracranial hypertension, idiopathic 10.1 POMC AQP1
43 somatoform disorder 10.1 TACR1 TAC1 OPRM1
44 gilles de la tourette syndrome 10.1 HTR3B HTR3A HTR1A ADRA2A
45 melancholia 10.1 POMC HTR1A
46 sudden infant death syndrome 10.1 TACR1 TAC1 HTR3A HTR1A
47 van maldergem syndrome 1 10.1 POMC FOS
48 central hypoventilation syndrome, congenital 10.1 TACR1 TAC1 HTR1A FOS
49 irritable bowel syndrome 10.1 TAC1 POMC HTR3A HTR1A
50 somatization disorder 10.0 TAC1 POMC PCSK5 HTR1A

Graphical network of the top 20 diseases related to Motion Sickness:



Diseases related to Motion Sickness

Symptoms & Phenotypes for Motion Sickness

Human phenotypes related to Motion Sickness:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 31 HP:0000707

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neuro:
motion sickness

Clinical features from OMIM®:

158280 (Updated 05-Mar-2021)

UMLS symptoms related to Motion Sickness:


nausea and vomiting, constipation, polydipsia, fatigue, fever, abdominal pain, vertigo, chest pain, headache, pruritus, syncope, cyanosis, diarrhea, edema, pain, nausea, chills, chronic pain, asthenia, sciatica, halitosis, dyspepsia, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, coughing, vertigo/dizziness, signs and symptoms, respiratory, symptoms, heartburn, gastrointestinal gas, oral manifestations, pelvic pain, vomiting alone, eye manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, skin manifestations, renal colic, mobility limitation, prodromal symptoms, medically unexplained symptoms

MGI Mouse Phenotypes related to Motion Sickness:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 9.76 AQP1 FOS HRH1 HTR1A HTR1B HTR3B
2 behavior/neurological MP:0005386 9.73 ADRA2A AQP1 BLOC1S5 FOS HRH1 HTR1A
3 renal/urinary system MP:0005367 9.17 AQP1 BLOC1S5 HRH1 HTR3A PCSK5 POMC

Drugs & Therapeutics for Motion Sickness

Drugs for Motion Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Promethazine Approved, Investigational Phase 4 60-87-7 4927
3 Ginger Approved Phase 4
4
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
5
Meclizine Approved Phase 4 569-65-3 4034
6 Hypnotics and Sedatives Phase 4
7 Dermatologic Agents Phase 4
8 Anesthetics, Local Phase 4
9 Histamine Antagonists Phase 4
10
Histamine Phosphate Phase 4 51-74-1 65513
11 Anti-Allergic Agents Phase 4
12 Histamine H1 Antagonists Phase 4
13
Scopolamine Approved, Investigational Phase 2, Phase 3 51-34-3, 6533-68-2 5184
14 Gastrointestinal Agents Phase 2, Phase 3
15 Neurotransmitter Agents Phase 2, Phase 3
16 Antiemetics Phase 2, Phase 3
17 Anesthetics Phase 2, Phase 3
18 Cholinergic Antagonists Phase 2, Phase 3
19 Mydriatics Phase 2, Phase 3
20 Muscarinic Antagonists Phase 2, Phase 3
21 Butylscopolammonium Bromide Phase 2, Phase 3
22 Cholinergic Agents Phase 2, Phase 3
23 Parasympatholytics Phase 2, Phase 3
24 Bromides Phase 2, Phase 3
25
Morphine Approved, Investigational 57-27-2 5288826
26
Rizatriptan Approved 144034-80-0, 145202-66-0 5078
27
tannic acid Approved 1401-55-4
28
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
29
Physostigmine Approved, Investigational Early Phase 1 57-47-6 5983
30 Serotonin 5-HT1 Receptor Agonists
31 Serotonin Receptor Agonists
32 Anti-Inflammatory Agents Early Phase 1
33 Analgesics, Non-Narcotic Early Phase 1
34 Cyclooxygenase Inhibitors Early Phase 1
35 Salicylates Early Phase 1
36 Anti-Inflammatory Agents, Non-Steroidal Early Phase 1
37 Antirheumatic Agents Early Phase 1
38 Analgesics Early Phase 1
39
Glycopyrrolate Early Phase 1 596-51-0 3494
40 Cholinesterase Inhibitors Early Phase 1
41
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Motion Sickness Medications and Vestibular Time Constant Unknown status NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
2 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels Completed NCT02136420 Phase 4 Promethazine;Placebo
3 Clinical Evaluation of the Use of Ginger Extract in the Management of Motion Sickness Completed NCT03755596 Phase 4 Z. officinale extract
4 Meclizine Plasma Levels in Responders and Non-responders Not yet recruiting NCT04482985 Phase 4 Meclizine Hydrochloride
5 A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness Completed NCT04184115 Phase 3 DPI-386 Nasal Gel;Placebos
6 A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness Completed NCT03986905 Phase 3 Scopolamine Nasal Gel
7 Motion Syros: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Tradipitant in the Treatment of Motion Sickness Recruiting NCT04327661 Phase 3 Tradipitant High Dose;Tradipitant Low Dose;Placebo
8 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of DPI-386 Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness Recruiting NCT04272255 Phase 3 scopolamine HBr;Transdermal Scopolamine
9 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety, Efficacy and Pharmacokinetics of DPI-386 Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects With Open-Label Follow-Up Recruiting NCT03988530 Phase 3 Scopolamine
10 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Defender Pharmaceuticals Inc, (DPI)-386 Nasal Gel on Ocean-Going Vessels for the Prevention and Treatment of Nausea Associated With Motion Sickness Recruiting NCT03920644 Phase 3 Scopolamine Transdermal Patch [Transderm Scop];Scopolamine;Placebo Patch;Placebo Gel
11 Pharmacokinetic and Efficacy Profile of Low-Dose Intranasal Scopolamine Spray for Motion Sickness Terminated NCT02155309 Phase 2, Phase 3 Scopolamine;Placebo
12 A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of the Safety, Pharmacokinetics, and Efficacy of DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness Terminated NCT04219982 Phase 2, Phase 3 DPI-386 Nasal Gel;DPI-386 Placebo Nasal Gel;Transderm Scop®
13 Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study Completed NCT02241629 Phase 2 placebo;levo phencynonate hydrochloride
14 Effects of Transdermal Scopolamine on Occupational Performance Completed NCT00374478 Phase 2 Scopolamine
15 Motion Sifnos: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness Completed NCT03772340 Phase 2 Tradipitant;Placebo
16 A Randomized, Single-center, Crossover, Comparative Bioavailability and Adhesion Performance Study, Comparing Single Administrations of a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants. Completed NCT02839135 Phase 1 Reformulated scopolamine patch;Marketed scopolamine patch
17 Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe Unknown status NCT02911402
18 Virtual Reality Stress and Relief Project, Research on Quantification of VR Related Stress, Motion Sickness and Visual Fatigue Unknown status NCT02986555
19 Risk Factors for Nausea, Vomiting and Pruritus After Neuraxial Morphine for Cesarean Section Unknown status NCT03178058
20 Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers Completed NCT02177890
21 Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs Completed NCT00360282 Rizatriptan
22 A Pilot Study to Assess the Feasibility and the Preliminary Efficacy of a Virtual Reality Distraction Intervention for Pain Management and Anxiety in Children With Burn Injuries During Hydrotherapy Completed NCT02794103
23 Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea - a Randomized Clinical Trial With Sham-conditions Completed NCT02660970 Iberogast
24 Virtual Reality in Labor and Delivery for Reduction in Pain Recruiting NCT03437031
25 INtervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer's Symptomatic Expression: The INCREASE Study Active, not recruiting NCT02849639 Early Phase 1 Scopolamine patch
26 Temporal Synthesis of Vestibular and Extra-Vestibular Sensory Signals Enrolling by invitation NCT04196933
27 Sensory Re-weighting Training for Orientation and Equilibrium: A Pilot Trial for the Treatment of Visually-induced Dizziness Not yet recruiting NCT04331561
28 High-precision Immersive Robotic Environment for Sensorimotor Training Not yet recruiting NCT04420949
29 Toward a Computationally-Informed, Personalized Treatment for Hallucinations Not yet recruiting NCT04366518 Early Phase 1 Physostigmine Salicylate;Scopolamine
30 Virtual Reality MObility for Burn Patients (VR-MOBILE): A Pilot Randomized Clinical Trial Not yet recruiting NCT04538573 Standard Treatment
31 Nano-X Image Guidance: CBCT With Gravity-induced Motion Not yet recruiting NCT04488224 Early Phase 1
32 Effects of Vertical Prism on the Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria: A Randomized, Double-blinded, Placebo-controlled, Cross-over Study Terminated NCT00785135

Search NIH Clinical Center for Motion Sickness

Inferred drug relations via UMLS 71 / NDF-RT 51 :


bromodiphenhydramine
Bromodiphenhydramine hydrochloride
chlorcyclizine
Chlorcyclizine hydrochloride
Dimenhydrinate
Diphenhydramine
Diphenhydramine Citrate
Diphenhydramine Hydrochloride
Meclizine
Meclizine Hydrochloride
Promethazine
PROMETHAZINE HYDROBROMIDE
Promethazine Hydrochloride

Cochrane evidence based reviews: motion sickness

Genetic Tests for Motion Sickness

Anatomical Context for Motion Sickness

MalaCards organs/tissues related to Motion Sickness:

40
Brain, Eye, Heart, Skin, Breast, Cerebellum, Amygdala

Publications for Motion Sickness

Articles related to Motion Sickness:

(show top 50) (show all 2586)
# Title Authors PMID Year
1
Motion sickness: an evolutionary hypothesis. 61 57
301659 1977
2
Sea Voyage Training and Motion Sickness Effects on Working Ability and Life Quality After Landing. 42 61
33468289 2021
3
Exploring the Participant-Related Determinants of Simulator Sickness in a Physical Motion Car Rollover Simulation as Measured by the Simulator Sickness Questionnaire. 42
32993081 2020
4
Joint and individual effectiveness of galvanic cutaneous stimulation and tactile stimulation at decreasing Simulator Adaptation Syndrome. 42
33057365 2020
5
Exploring the utility of EDA and skin temperature as individual physiological correlates of motion sickness. 61
33276213 2021
6
Ocular counter-rolling in scuba divers with motion sickness. 61
32828593 2021
7
Suitability and Comparison of Questionnaires Assessing Virtual Reality-Induced Symptoms and Effects and User Experience in Virtual Environments. 61
33567570 2021
8
Comparison of efficacy dimenhydrinate and metoclopramide in the treatment of nausea due to vertigo; a randomized study. 61
33360021 2021
9
PCA of waveforms and functional PCA: A primer for biomechanics. 61
33429072 2021
10
A Virtual Reality Exergame to Engage Adolescents in Physical Activity: Mixed Methods Study Describing the Formative Intervention Development Process. 61
33538697 2021
11
Individual differences in the temporal progression of motion sickness and anxiety: the role of passengers' trait anxiety and motion sickness history. 61
33566736 2021
12
The effects of different seat suspension types on occupants' physiologic responses and task performance: implications for autonomous and conventional vehicles. 61
33578066 2021
13
Measurements of human tolerance to horizontal rotation within an MRI scanner: Towards gantry-free radiation therapy. 61
33377303 2021
14
Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study. 61
33397273 2021
15
Test-retest reliability of the virtual reality sickness evaluation using electroencephalography (EEG). 61
33359731 2021
16
The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy. 61
33549001 2021
17
Efficacy of augmented visual environments for reducing sickness in autonomous vehicles. 61
33065467 2021
18
The effect of water immersion on vection in virtual reality. 61
33441803 2021
19
Graves' disease with motion sickness: A case report. 61
33444592 2021
20
Beyond sensory conflict: The role of beliefs and perception in motion sickness. 61
33465124 2021
21
Resting-state functional connectivity predicts recovery from visually induced motion sickness. 61
33442756 2021
22
A novel method for reducing motion sickness susceptibility through training visuospatial ability - A two-part study. 61
32920224 2021
23
Electrogastrography in Autonomous Vehicles-An Objective Method for Assessment of Motion Sickness in Simulated Driving Environments. 61
33466805 2021
24
Acute onset psychosis with complex neurobehavioural symptomatology following the intramuscular injection of hyoscine butylbromide: a case report with an overview of the literature. 61
33376193 2020
25
The role of the vestibular system in value attribution to positive and negative reinforcers. 61
33130427 2020
26
Derealization and motion-perception related to repeated exposure to 3T Magnetic Resonance Image scanner in healthy adults. 61
33325422 2020
27
Vestibular modulation of skin sympathetic nerve activity in sopite syndrome induced by low-frequency sinusoidal motion. 61
32965160 2020
28
5HT3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. 61
33274555 2020
29
Knowing What's Coming: Unpredictable Motion Causes More Motion Sickness. 61
31590575 2020
30
Postural precursors of motion sickness in head-mounted displays: drivers and passengers, women and men. 61
32780665 2020
31
Stress Response of Beagle Dogs to Repeated Short-Distance Road Transport. 61
33202655 2020
32
Role of Phosphatidylethanolamine Biosynthesis in Herpes Simplex Virus 1-Infected Cells in Progeny Virus Morphogenesis in the Cytoplasm and in Viral Pathogenicity In Vivo. 61
32999028 2020
33
Routine Vestibular Tests May Point Out Vestibular Subtype of Seasickness Only. 61
33334405 2020
34
Objective and subjective responses to motion sickness: the group and the individual. 61
33249541 2020
35
Effects of physical driving experience on body movement and motion sickness among passengers in a virtual vehicle. 61
33242143 2020
36
Standing balance of vehicle passengers: The effect of vehicle motion, task performance on post-drive balance. 61
32937271 2020
37
Intraoperative systemic vascular resistance is associated with postoperative nausea and vomiting after laparoscopic hysterectomy. 61
33195649 2020
38
Cognitive Training Using Fully Immersive, Enriched Environment Virtual Reality for Patients With Mild Cognitive Impairment and Mild Dementia: Feasibility and Usability Study. 61
33052115 2020
39
Examining potential effects of arousal, valence, and likability of music on visually induced motion sickness. 61
32757060 2020
40
A Deep Motion Sickness Predictor Induced by Visual Stimuli in Virtual Reality. 61
33079678 2020
41
Imbalance, motion sensitivity, anxiety and handicap in vestibular migraine and migraine only patients. 61
32178946 2020
42
An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. 61
32767766 2020
43
Nausea and vomiting of pregnancy: associations with personal history of nausea and affected relatives. 61
32653947 2020
44
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. 61
33023657 2020
45
HeadJoystick: Improving Flying in VR using a Novel Leaning-Based Interface. 61
32946395 2020
46
A head-worn display ("smart glasses") has adverse impacts on the dynamics of lateral position control during gait. 61
32717669 2020
47
Virtual reality for teaching and learning in crime scene investigation. 61
32873386 2020
48
Risk of postoperative nausea and vomiting in hip and knee arthroplasty: a prospective cohort study after spinal anaesthesia including intrathecal morphine. 61
32972366 2020
49
Patterns of illness and injury on Antarctic research cruises, 2004-2019: a descriptive analysis. 61
32657340 2020
50
Understanding users' characteristics in the selection of vehicle seating configurations and positions in fully automated vehicles. 61
32926638 2020

Variations for Motion Sickness

Expression for Motion Sickness

Search GEO for disease gene expression data for Motion Sickness.

Pathways for Motion Sickness

Pathways related to Motion Sickness according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 TACR1 TAC1 POMC OPRM1 HTR1B HTR1A
2 12.07 POMC HTR1B HTR1A FOS
3 11.88 TACR1 TAC1 HTR3A HTR1A
4 11.77 TACR1 FOS AQP1
5 11.73 POMC OPRM1 FOS
6
Show member pathways
11.72 HTR3B HTR3A HTR1B HTR1A
7 11.62 HTR3B HTR3A HTR1B HTR1A
8
Show member pathways
11.3 HTR1B HTR1A HRH1 ADRA2A
9 10.78 HTR3A HTR1B HTR1A
10
Show member pathways
10.68 HTR3B HTR3A
11 10.25 TACR1 TAC1
12
Show member pathways
10.16 HTR1B HTR1A ADRA2A

GO Terms for Motion Sickness

Cellular components related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.1 TACR1 TAC1 OR2M2 OPRM1 HTR3B HTR3A
2 synapse GO:0045202 9.73 TAC1 HTR3B HTR3A HTR1A HRH1 CBLN4
3 integral component of presynaptic membrane GO:0099056 9.33 OPRM1 HTR3A HTR1B
4 integral component of plasma membrane GO:0005887 9.28 TACR1 OPRM1 HTR3B HTR3A HTR1B HTR1A
5 serotonin-activated cation-selective channel complex GO:1904602 8.96 HTR3B HTR3A

Biological processes related to Motion Sickness according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 TACR1 POMC OR2M2 OPRM1 HTR3B HTR3A
2 G protein-coupled receptor signaling pathway GO:0007186 9.81 TACR1 TAC1 POMC OR2M2 OPRM1 HTR1B
3 response to ethanol GO:0045471 9.76 OPRM1 HTR3A HTR1B
4 neuropeptide signaling pathway GO:0007218 9.73 TAC1 POMC OPRM1
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.69 TACR1 OPRM1 HRH1
6 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.67 OPRM1 HTR1B ADRA2A
7 response to cocaine GO:0042220 9.63 OPRM1 HTR3A HTR1B
8 regulation of vasoconstriction GO:0019229 9.59 HTR1A ADRA2A
9 response to pain GO:0048265 9.58 TACR1 TAC1
10 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.58 HTR1B HTR1A HRH1
11 vasoconstriction GO:0042310 9.57 HTR1B HTR1A
12 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 OPRM1 HTR1B HTR1A HRH1
13 behavior GO:0007610 9.55 HTR1B HTR1A
14 regulation of behavior GO:0050795 9.54 HTR1B HTR1A
15 tachykinin receptor signaling pathway GO:0007217 9.52 TACR1 TAC1
16 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.48 HTR1B HTR1A
17 detection of abiotic stimulus GO:0009582 9.43 TACR1 TAC1
18 chemical synaptic transmission GO:0007268 9.43 TAC1 HTR3B HTR3A HTR1B HTR1A HRH1
19 positive regulation of saliva secretion GO:0046878 9.37 TAC1 AQP1
20 serotonin receptor signaling pathway GO:0007210 8.8 HTR3B HTR3A HTR1A

Molecular functions related to Motion Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.7 TACR1 OR2M2 OPRM1 HTR1B HTR1A HRH1
2 G protein-coupled serotonin receptor activity GO:0004993 9.43 HTR1B HTR1A HRH1
3 serotonin-gated cation-selective channel activity GO:0022850 9.32 HTR3B HTR3A
4 serotonin binding GO:0051378 9.13 HTR3A HTR1B HTR1A
5 neurotransmitter receptor activity GO:0030594 9.02 HTR3B HTR3A HTR1B HTR1A HRH1

Sources for Motion Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....